By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Alumis (ALMS) due to its high valuation, reliance on a single pipeline, and significant competition in the TYK2 inhibitor space. The stock's 355% YTD run-up and high market cap ($2.8B) relative to TTM revenue ($8.4M) and net loss ($237M) also raise concerns. The key risk is the binary clinical outcomes and competition from approved agents, while the key opportunity is a potential M&A exit based on differentiated Phase 2b data.
Risk: Binary clinical outcomes and competition from approved agents
Opportunity: Potential M&A exit based on differentiated Phase 2b data
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Deep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices).
Meanwhile, the quarter-end position value changed by $149.20 million, reflecting the new stake.
The transaction represented a 2.76% increase relative to Deep Track Capital’s 13F reportable assets under management (AUM).
On May 15, 2026, Deep Track Capital disclosed a new position in Alumis (NASDAQ:ALMS), acquiring 6,772,595 shares—an estimated $169.31 million trade based on quarterly average pricing.
According to a May 15, 2026 SEC filing, Deep Track Capital reported acquiring 6,772,595 shares of Alumis (NASDAQ:ALMS) during the first quarter of 2026. The estimated transaction value was $169.31 million, based on the period’s average unadjusted closing price. As of March 31, 2026, the fund’s Alumis stake was valued at $149.20 million, reflecting both the purchase and stock price changes during the quarter.
NASDAQ:GPCR: $206.29 million (4.3% of AUM)
As of Friday, shares of Alumis were priced at $22.02, up about 355% over the past year and well outperforming the S&P 500, which is up about 28% in the same period.
| Metric | Value | |---|---| | Price (as of Friday) | $22.02 | | Market capitalization | $2.8 billion | | Revenue (TTM) | $8.40 million | | Net income (TTM) | ($237.41 million) |
Alumis is a biotechnology company specializing in the development of novel therapies for autoimmune and neuroinflammatory conditions. It leverages expertise in allosteric TYK2 inhibition to advance a pipeline of differentiated clinical candidates. With a focus on unmet medical needs, Alumis aims to establish a competitive edge through innovative science and targeted clinical development strategies.
Deep Track has a history of making concentrated healthcare investments, and Alumis fits that playbook as a late-stage biotech with multiple shots on goal and several potentially value-defining catalysts over the next year.
The story is increasingly centered on envudeucitinib, the company's TYK2 inhibitor for autoimmune diseases. Recent Phase 3 psoriasis data showed PASI 90 response rates of 68.0% and 62.1% by Week 24, with PASI 100 rates reaching 41.0% and 39.5%. Management says it remains on track to submit an NDA in the fourth quarter of this year, while potentially pivotal Phase 2b lupus data are expected in the third quarter.
CEO Martin Babler said the results reinforce the drug's potential to "reshape the psoriasis treatment landscape" and described envudeucitinib as a potential "pipeline in a pill" with opportunities across additional immune-mediated diseases.
Financially, Alumis ended the quarter with $569.5 million in cash, cash equivalents, and marketable securities and expects that capital to fund operations into the fourth quarter of 2027.
For long-term investors, the thesis is straightforward. If upcoming lupus data and the planned psoriasis filing go well, today's valuation could look conservative. If either disappoints, the stock's remarkable run may prove difficult to sustain.
Before you buy stock in Alumis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alumis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 24, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"ALMS's $2.8B valuation already prices in successful commercialization of an unapproved asset in a competitive TYK2 space."
Deep Track's $169M ALMS purchase signals conviction in envudeucitinib's Phase 3 psoriasis data and upcoming lupus readout, yet the stock's 355% run already embeds substantial optimism. With $2.8B market cap, $8.4M TTM revenue, and $237M net loss, the position represents a high-conviction biotech bet rather than broad validation. Cash runway to 2027Q4 mitigates near-term dilution risk, but TYK2 competition from approved agents and binary clinical outcomes remain unaddressed. The quarter-end stake decline to $149M hints at post-purchase price pressure.
Positive lupus Phase 2b data in Q3 plus NDA acceptance could trigger re-rating well above current levels, validating the fund's timing despite the prior run-up.
"ALMS is priced for flawless execution across two major catalysts within 18 months with no margin for setback, competitive pressure, or regulatory friction."
Deep Track's $169M entry is meaningful but the article conflates fund buying with investment merit. ALMS trades at ~333x TTM revenue on $8.4M sales against a $237M net loss—valuation is entirely contingent on envudeucitinib Phase 3 psoriasis and Phase 2b lupus data. The 355% YTD move suggests priced-in optimism; Deep Track bought at $25 average, now $22, implying the fund is already underwater. Runway to Q4 2027 is tight for a clinical-stage biotech. The article omits competitive TYK2 landscape (Pfizer, Janssen active here) and doesn't quantify peak-sales assumptions justifying current market cap.
If lupus Phase 2b data are strong and psoriasis NDA clears smoothly, ALMS could be a $5B+ asset by 2028—making Deep Track's entry a steal and the 355% run just the beginning of a multi-year bull case.
"Alumis is currently priced for a flawless clinical execution that ignores the significant execution risks and competitive saturation within the TYK2 inhibitor market."
The 355% run-up in Alumis (ALMS) makes this a classic 'chase' scenario. While Deep Track Capital’s $169 million entry provides a veneer of institutional validation, investors must distinguish between early-stage biotech promise and commercial reality. With $8.4 million in TTM revenue against a $2.8 billion market cap, the valuation is entirely predicated on the successful commercialization of envudeucitinib. The TYK2 inhibitor space is increasingly crowded—Bristol Myers Squibb’s Sotyktu has already set a high bar for efficacy and safety. Alumis is priced for perfection; any delay in their Q4 NDA filing or a 'meh' result in the Q3 Phase 2b lupus trial will likely trigger a sharp, violent mean reversion.
If envudeucitinib proves superior in head-to-head tolerability against existing TYK2 inhibitors, Alumis could become a prime M&A target for a Big Pharma player looking to bolster their immunology franchise, justifying the premium.
"Alumis’ valuation is bets-on-clinical-success; without NDA approval and supportive lupus data, the stock faces meaningful downside despite the investor interest."
Deep Track Capital’s $169M new stake in Alumis signals confidence but doesn’t alter the fundamental risk: Alumis is pre-commercial with a sizable cash burn and a single pipeline driving valuation. The stock trades near a $2.8B market cap with TTM revenue of $8.4M and a large net loss, meaning upside hinges on NDA filing for envudeucitinib (PSO) in Q4 2026 and pivotal lupus data in Q3 2026. While Phase 3 psoriasis data look encouraging, regulatory approval, safety signals, competition from TYK2 inhibitors, and payer access could all derail the thesis. The rally may be momentum-driven rather than fundamentals-led.
Even with strong data, regulatory risk remains high and a delayed or failed NDA could wipe out a large portion of the gains, regardless of Deep Track’s stake.
"Extended cash runway to 2027 materially reduces dilution risk that could worsen binary clinical outcomes beyond competition concerns."
Claude flags Deep Track underwater after buying at $25 versus $22 now, yet ignores how the Q4 2027 cash runway directly lowers dilution odds that would otherwise amplify downside on any lupus Phase 2b miss. That extended runway connects the valuation math to execution risk more than TYK2 competition alone, since no near-term financing overhang exists to compound binary outcomes.
"Extended cash runway reduces financing risk but is orthogonal to clinical risk—the dominant driver of ALMS downside."
Grok's cash runway argument conflates solvency with valuation. Q4 2027 runway eliminates *dilution* risk, not *clinical* risk—the real destroyer of biotech valuations. A failed Phase 2b lupus trial in Q3 2026 doesn't need dilution to crater the stock; it needs one data point. Runway buys time for execution, not insurance against binary outcomes. The two risks are orthogonal.
"The valuation is driven by M&A potential based on Phase 2b data, rendering the long-term cash runway and commercial dilution concerns secondary to competitive positioning."
Claude and Grok are debating the mechanics of the runway, but both miss the primary catalyst: the M&A exit. In the TYK2 space, Big Pharma isn't waiting for 2027 commercialization; they are looking for differentiated Phase 2b data to preemptively acquire. If Alumis shows superior tolerability, the 'cash runway' becomes irrelevant because a buyout happens at a premium. The real risk isn't dilution or clinical failure, but the 'winner-take-most' dynamic where Sotyktu dominates the market, leaving Alumis as a niche, unappealing asset.
"Runway extension defers dilution risk but does not shield the stock from data risk or possible financing needs; a strong data readout or expedited M&A is still required."
Grok’s point about a longer cash runway reducing dilution risk ignores the fact that runway postpones, not eliminates, dilution, and binary trial outcomes can still force dilutive financings or equity raises. Embedding valuation in a 2027 financing timetable risks a rerun if lupus Phase 2b or psoriasis data disappoints, or if a competitive TYK2 path accelerates, pushing M&A timelines. The contrarian risk is that the 'runway' becomes a mirage if data stalls.
The panel consensus is bearish on Alumis (ALMS) due to its high valuation, reliance on a single pipeline, and significant competition in the TYK2 inhibitor space. The stock's 355% YTD run-up and high market cap ($2.8B) relative to TTM revenue ($8.4M) and net loss ($237M) also raise concerns. The key risk is the binary clinical outcomes and competition from approved agents, while the key opportunity is a potential M&A exit based on differentiated Phase 2b data.
Potential M&A exit based on differentiated Phase 2b data
Binary clinical outcomes and competition from approved agents